FridayNov 05, 2021 10:52 am

German Cannabis Market Expected to Liberalize Post Election, RYAH Group Inc. (CSE: RYAH) Enters Germany Via Observational Study

German Social Democrat-led coalition expected to liberalize medical cannabis market  Analysts predict over one million medical cannabis patients in Germany by 2024, market estimated to reach $8.9 billion by 2028 RYAH entered German market via observational study with Four 20 Pharma GmbH RYAH provides IoT product ecosystem of volume-control devices, medicine-carrying components, mobile applications RYAH ecosystem offers reliable way for researchers and clinicians to develop well-controlled research environments Germany’s recent 2021 election is expected to result in a new political environment via a coalition containing cannabis-positive political factions that aim to liberalize the country’s plant-based medicine market (https://cnw.fm/z1BxY). RYAH Group…

Continue Reading

WednesdayNov 03, 2021 12:31 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio

Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://cnw.fm/iMVe3). EPIL-A21-1, which will be…

Continue Reading

MondayNov 01, 2021 1:34 pm

Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production

Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly listed Ginkgo Bioworks Holdings Inc., in what is the largest-ever biotechnology go-public transaction Ginkgo Bioworks is known for its work in the commercial-scale production of a rare cannabinoid, CBG, for use in a multitude of industrial needs InMed uses multiple manufacturing approaches to synthetically produce rare cannabinoids, including CBC which is currently sold through its subsidiary BayMedica The success of the Ginkgo IPO suggests the marketplace value associated with the production of rare cannabinoids Special purpose acquisition company (“SPAC”) Soaring Eagle Acquisition Corp. (NASDAQ: SRNGU,…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977